CVRx, Inc.

CVRx is a medical technology company specializing in neuromodulation therapies for heart failure management. The company's flagship product, Barostim, is an implantable device that delivers gentle electrical pulses to baroreceptors on the carotid artery to modulate neural signals and reduce heart failure symptoms. Clinical evidence demonstrates that Barostim improves exercise capacity (patients walk approximately 60 yards farther in 6-minute testing), quality of life (3x greater improvement vs. medication alone), and symptom relief, with 94% of patients experiencing significant improvement in quality of life, exercise capacity, or heart failure symptoms. The minimally invasive implant procedure typically takes about one hour with same-day discharge and a 97% freedom-from-complications rate. CVRx provides comprehensive support services to healthcare providers, including patient access assistance and reimbursement support to ensure eligible patients can access baroreflex activation therapy.